Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 15, 2018. The report discloses the company's financial results for the quarter ended March 31, 2018. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It serves as a notification that the quarterly results have been announced and directs readers to the attached press release for details.
Guidance, Outlook, and Risks
The text does not contain management commentary, guidance, outlook, or specific risk factors. It includes a standard disclaimer stating that the information in this report and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference into other filings unless expressly stated.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (the press release), as they are absent from the 8-K body text.
- Confirm the company name is Aerpio Pharmaceuticals, Inc., noting the discrepancy with the "Whitehawk Therapeutics" label in the request metadata.
- Review the full press release for any updates on clinical trial progress or pipeline developments, which are typical for this sector but not detailed in this summary.
- Check subsequent filings for any restatements or updates to the March 31, 2018 results.